Effects of metabolized and unmetabolized arachidonate on rat platelet shape change.

M. G. Lampugnani, G. de Gaetano

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Arachidonate (0.12-1.5 mM) initiated a concentration-dependent, saturable shape change of rat platelets suspended in citrated plasma. Interaction of arachidonate with platelets led to the formation of active metabolites that appeared to be the actual inducers of shape change. Among these, prostaglandin endoperoxides rather than thromboxane A2 seemed necessary for shape change. No role of the products of the lipoxygenase pathway could be shown. In the presence of cyclooxygenase and lipoxygenase inhibitors, arachidonate (0.25-0.5 mM) prevented platelet shape change induced by the endoperoxide analog U-46619 but not by other agonists such as ADP or serotonin. Arachidonate acts therefore as both an agonist and an antagonist of platelet shape change. The agonistic effect requires arachidonate metabolism while the antagonistic activity seems to be linked to the fatty acid molecule itself.

Original languageEnglish
JournalThe American journal of physiology
Volume247
Issue number3 Pt 2
Publication statusPublished - Sep 1984

Fingerprint

Blood Platelets
Prostaglandin Endoperoxides
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Lipoxygenase Inhibitors
Thromboxane A2
Lipoxygenase
Cyclooxygenase Inhibitors
Platelet Aggregation Inhibitors
Adenosine Diphosphate
Serotonin
Fatty Acids

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effects of metabolized and unmetabolized arachidonate on rat platelet shape change. / Lampugnani, M. G.; de Gaetano, G.

In: The American journal of physiology, Vol. 247, No. 3 Pt 2, 09.1984.

Research output: Contribution to journalArticle

@article{1b01dd92bc0148b187cd5036d520eb78,
title = "Effects of metabolized and unmetabolized arachidonate on rat platelet shape change.",
abstract = "Arachidonate (0.12-1.5 mM) initiated a concentration-dependent, saturable shape change of rat platelets suspended in citrated plasma. Interaction of arachidonate with platelets led to the formation of active metabolites that appeared to be the actual inducers of shape change. Among these, prostaglandin endoperoxides rather than thromboxane A2 seemed necessary for shape change. No role of the products of the lipoxygenase pathway could be shown. In the presence of cyclooxygenase and lipoxygenase inhibitors, arachidonate (0.25-0.5 mM) prevented platelet shape change induced by the endoperoxide analog U-46619 but not by other agonists such as ADP or serotonin. Arachidonate acts therefore as both an agonist and an antagonist of platelet shape change. The agonistic effect requires arachidonate metabolism while the antagonistic activity seems to be linked to the fatty acid molecule itself.",
author = "Lampugnani, {M. G.} and {de Gaetano}, G.",
year = "1984",
month = "9",
language = "English",
volume = "247",
journal = "American Journal of Physiology",
issn = "0363-6119",
publisher = "American Physiological Society",
number = "3 Pt 2",

}

TY - JOUR

T1 - Effects of metabolized and unmetabolized arachidonate on rat platelet shape change.

AU - Lampugnani, M. G.

AU - de Gaetano, G.

PY - 1984/9

Y1 - 1984/9

N2 - Arachidonate (0.12-1.5 mM) initiated a concentration-dependent, saturable shape change of rat platelets suspended in citrated plasma. Interaction of arachidonate with platelets led to the formation of active metabolites that appeared to be the actual inducers of shape change. Among these, prostaglandin endoperoxides rather than thromboxane A2 seemed necessary for shape change. No role of the products of the lipoxygenase pathway could be shown. In the presence of cyclooxygenase and lipoxygenase inhibitors, arachidonate (0.25-0.5 mM) prevented platelet shape change induced by the endoperoxide analog U-46619 but not by other agonists such as ADP or serotonin. Arachidonate acts therefore as both an agonist and an antagonist of platelet shape change. The agonistic effect requires arachidonate metabolism while the antagonistic activity seems to be linked to the fatty acid molecule itself.

AB - Arachidonate (0.12-1.5 mM) initiated a concentration-dependent, saturable shape change of rat platelets suspended in citrated plasma. Interaction of arachidonate with platelets led to the formation of active metabolites that appeared to be the actual inducers of shape change. Among these, prostaglandin endoperoxides rather than thromboxane A2 seemed necessary for shape change. No role of the products of the lipoxygenase pathway could be shown. In the presence of cyclooxygenase and lipoxygenase inhibitors, arachidonate (0.25-0.5 mM) prevented platelet shape change induced by the endoperoxide analog U-46619 but not by other agonists such as ADP or serotonin. Arachidonate acts therefore as both an agonist and an antagonist of platelet shape change. The agonistic effect requires arachidonate metabolism while the antagonistic activity seems to be linked to the fatty acid molecule itself.

UR - http://www.scopus.com/inward/record.url?scp=0021485129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021485129&partnerID=8YFLogxK

M3 - Article

VL - 247

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6119

IS - 3 Pt 2

ER -